The FDA has approved mFLUSIVA, the first mRNA-based influenza vaccine, for individuals aged 50 and older, with availability expected in the coming weeks.

The U.S. Food and Drug Administration has approved Moderna's mFLUSIVA, a new seasonal influenza vaccine utilizing mRNA technology. The vaccine is authorized for use in individuals aged 50 and older. Moderna announced that the shot will be available within a few weeks, in time for the 2026-2027 respiratory virus season in the United States.

Clinical Research and Efficacy

Moderna conducted research involving more than 40,000 participants to evaluate the vaccine. According to the company, the findings indicate that mFLUSIVA is safe and appears to provide stronger protection compared to traditional influenza vaccines. Public health officials have noted that mRNA technology allows for faster updates and production than standard vaccine methods, which could prove beneficial if a new flu strain emerges unexpectedly or if a flu pandemic occurs.

Regulatory and Political Context

The FDA's review process for the vaccine followed a period of scrutiny regarding mRNA technology within the current administration. Although the agency initially declined to review the shot, it later moved forward following pressure from the pharmaceutical industry and public health experts. In June, an independent panel of outside advisers convened by the FDA voted unanimously to recommend the vaccine's approval.

Expert Perspectives

The approval has drawn varied reactions from medical and health experts. Michael Osterholm of the University of Minnesota described the development as a critical step in advancing influenza vaccine technology. Dr. Jeanne Marrazzo of the Infectious Disease Society of America noted that the decision signals FDA openness to the mRNA platform. Conversely, Dr. Brian Hooker of Children's Health Defense expressed concerns regarding the newness of the technology and the level of study conducted on its implications.